Relationship between mean volume voided and incontinence in children with overactive bladder treated with solifenacin: post hoc analysis of a phase 3 randomised clinical trial

Robert Snijder, Brigitte Bosman, Otto Stroosma, Marja Agema, Robert Snijder, Brigitte Bosman, Otto Stroosma, Marja Agema

Abstract

This post hoc Poisson regression analysis investigated the relationship between mean volume voided and incontinence episodes/24 h after fixed frequency adjustment in children with overactive bladder from the LION study, a phase 3, double-blind, randomised, placebo-controlled, sequential, dose-titration solifenacin trial. Patients were aged 5-< 12 years with ≥ 4 episodes of daytime incontinence during a 7-day pre-baseline diary period. The dependent variable was the mean number of incontinence episodes/24 h at the end of study. Explanatory variables included treatment, mean number of incontinence episodes/24 h at baseline, and change from baseline to end of study in mean volume voided. Statistical significance and goodness of fit were analysed using the Pearson's chi-square test. A negative estimate was found between the dependent variable 'incontinence' and both mean volume voided and daytime maximum volume voided/micturition (an increase in mean volume voided or daytime maximum volume voided/micturition would lead to a reduction in incontinence; P = 0.0014 and P = 0.0317, respectively). The model was a good fit to the data in both analyses with a Pearson's chi-square goodness-of-fit criteria of 0.8.Conclusion: Increase in mean volume voided was significantly correlated to reduction in incontinence episodes/24 h in children with overactive bladder treated with solifenacin.This study is registered at ClinicalTrials.gov : NCT01565707. What is known: • Mean volume voided per micturition is used as an indicator of treatment efficacy, with increases noted as number of incontinence episodes (and micturition frequency) decrease. • The relationship between mean volume voided and incontinence episodes is not clearly understood. What is new: • Increase in mean volume voided significantly correlated to reduction in incontinence in solifenacin-treated children with overactive bladder (Poisson regression model analysis). • Compared with placebo, solifenacin-treated children had a lower predicted number of incontinence episodes/24 h.

Keywords: Children; Incontinence; Mean volume voided; Overactive bladder; Solifenacin.

Conflict of interest statement

Robert Snijder is an employee of Astellas Pharma Europe BV; Brigitte Bosman, Otto Stroosma, and Marja Agema were employees of Astellas Pharma Europe BV at the time of the study.

Figures

Fig. 1
Fig. 1
Validity of Poisson regression model with MVV/micturition a or DMaxVV b as predictors of incontinence. Response Variable (Y-axis) represents the predicted number of incontinence episodes/24 h at EoS. Predictor Variable (X-axis) represents the change from baseline to EoS in MVV a or DMaxVV b

References

    1. Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, Rittig S, Vande Walle J, von Gontard A, Wright A, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn. 2016;35:471–481. doi: 10.1002/nau.22751.
    1. Blaivas JG. Overactive bladder: symptom or syndrome? BJU Int. 2003;92:521–522. doi: 10.1046/j.1464-410X.2003.04445.x.
    1. Madersbacher H. Overactive bladder: a clinical entity or a marketing hype? Eur Urol. 2005;47:273–276. doi: 10.1016/j.eururo.2004.10.015.
    1. Tikkinen KAO, Auvinen A. Does the imprecise definition of overactive bladder serve commercial rather than patient interests? Eur Urol. 2012;61:746–748. doi: 10.1016/j.eururo.2011.12.013.
    1. Amundsen CL, Parsons M, Cardozo L, Vella M, Webster GD, Coats AC. Bladder diary volume per void measurements in detrusor overactivity. J Urol. 2006;176:2530–2534. doi: 10.1016/j.juro.2006.08.009.
    1. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33:17–30. doi: 10.1002/nau.22505.
    1. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A, on behalf of the YM-905 Study Group Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–310. doi: 10.1111/j.1464-410X.2004.04606.x.
    1. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J. 1999;10:283–289. doi: 10.1007/s001929970003.
    1. Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, Tubaro A (2018). EAU urinary incontinence guidelines. . Accessed 28 February 2020
    1. Lee S, Malhotra B, Creanga D, Carlsson M, Glue P. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol. 2009;9:55. doi: 10.1186/1471-2288-9-55.
    1. Cardozo L, Lisec M, Millard R, van Vierssen TO, Kuzmin I, Drogendijk TE, Huang M, Ridder AM. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919–1924. doi: 10.1097/01.ju.0000140729.07840.16.
    1. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–562. doi: 10.1016/j.eururo.2008.06.047.
    1. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–470. doi: 10.1016/j.eururo.2005.05.015.
    1. Newgreen D, Bosman B, Hollestein-Havelaar A, Dahler E, Besuyen R, Sawyer W, Bolduc S, Rittig S. Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol. 2017;71:483–490. doi: 10.1016/j.eururo.2016.08.061.
    1. Martina R, Kay R, van Maanen R, Ridder A. The analysis of incontinence episodes and other count data in patients with overactive bladder by Poisson and negative binomial regression. Pharm Stat. 2015;14:151–160. doi: 10.1002/pst.1664.
    1. Van Batavia JP, Combs AJ, Fast AM, Glassberg KI. Overactive bladder (OAB): a symptom in search of a disease – its relationship to specific lower urinary tract symptoms and conditions. J Pediatr Urol. 2017;13:277.e1–277.e4. doi: 10.1016/j.jpurol.2017.02.010.
    1. Chiang C-Y, Fan Y-H, Lin AT-L, Chen K-K. First morning voided volume as a valuable tool for evaluating patients with overactive bladder. Urol Sci. 2014;25:79–82. doi: 10.1016/j.urols.2014.03.002.
    1. Colli E, Parazzini F, Olivieri L, Cipriani S, Bertozzi R, Meschia M, Montorsi F. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials. Eur Urol. 2007;52:525–530. doi: 10.1016/j.eururo.2007.03.070.
    1. Ku JH, Lim DJ, Byun S-S, Paick J-S, Oh S-J. Nocturia in patients with lower urinary tract symptoms: association with diurnal voiding patterns. BJU Int. 2004;93:1005–1008. doi: 10.1111/j.1464-410X.2004.04770.x.
    1. van Brummen HJ, Heintz APM, van der Vaart CH. The association between overactive bladder symptoms and objective parameters from bladder diary and filling cystometry. Neurourol Urodyn. 2004;23:38–42. doi: 10.1002/nau.10162.
    1. Lose G, Fantl JA, Victor A, Walter S, Wells TL, Wyman J, Mattiasson A. Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction. Neurourol Urodyn. 1998;17:255–262. doi: 10.1002/(SICI)1520-6777(1998)17:3<255::AID-NAU10>;2-J.
    1. Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony) Eur Urol. 2015;67:577–588. doi: 10.1016/j.eururo.2014.02.012.
    1. Bower WF, Swithinbank L, de Jong T, de Kort LMO, Marschall-Kehrel D. Assessment of non-neurogenic incontinence and lower urinary tract symptoms in adolescents and young adults. Neurourol Urodyn. 2010;29:702–707. doi: 10.1002/nau.20829.
    1. Chung JM, Lee SD, Kang DI, Kwon DD, Kim KS, Kim SY, Kim HG, Moon DG, Park KH, Park YH, et al. Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study. Urology. 2009;73:63–67. doi: 10.1016/j.urology.2008.06.063.
    1. Hellström A, Hanson E, Hansson S, Hjälmås K, Jodal U. Micturition habits and incontinence at age 17 – reinvestigation of a cohort studied at age 7. Br J Urol. 1995;76:231–234. doi: 10.1111/j.1464-410X.1995.tb07681.x.
    1. Van Leijenhorst L, Zanolie K, Van Meel CS, Westenberg PM, Rombouts SARB, Crone EA. What motivates the adolescent? Brain regions mediating reward sensitivity across adolescence. Cereb Cortex. 2010;20:61–69. doi: 10.1093/cercor/bhp078.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera